I realise that exwannabe has, as per usual, downplayed this trial by casting doubt on whether the "autologous tumor lysate-pulsed dendritic cell vaccine" used is DCVax-L. Nobody has given a meaningful answer (just a comment on his intelligence) to his comments which doesn't surprise me as his constant denigration turns people off engaging with him.
However, in the whole of the scientific paper from Czechia there is no mention of either Northwest Biotherapeutics nor is the method of production of the dendrocytes from monocytes actually specified although the general method that is described follows the line of NWBO's method:
"...the vaccine was manufactured using autologous patient's peripheral blood monocytes obtained by leukapheresis and differentiated into DCs. Ex vivo immature DCs were loaded with autologous tumor lysate antigens and matured using lipopolysaccharide and interferon ? (IFN-?)".
Is this description of the manufacturing process sufficient to confirm that the method of production falls within being part of NWBO's intellectual property even though the actual process might be slightly different?
Market Data 
Markets 
AI
